(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/120290 A2 13 September 2012 (13.09.2012) P O P CT (51) International Patent Classification: Not classified (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (21) Number: International Application AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, PCT/GB20 12/050486 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 5 March 2012 (05.03.2012) HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (25) Filing Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (30) Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1103769.4 4 March 201 1 (04.03.201 1) GB 1103767.8 4 March 201 1 (04.03.201 1) GB (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): SANA GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, PHARMA AS [NO/NO]; Norway, Enebakkveien 117, N- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, 0680 Oslo (NO). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant (for BB only): GARDNER, Rebecca [GB/GB]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Dehns, St. Bride's House, 10 Salisbury Square, London, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Greater London EC4Y 8 D (GB). GW, ML, MR, NE, SN, TD, TG). (72) Inventors; and Published: (75) Inventors/Applicants (for US only): SVENNEVIG, Katja [NO/NO]; Torpmarka 32, N-1389 Heggedal (NO). — without international search report and to be republished KVALE, Espen [NO/NO]; Bjerregaardsgt. 49, N-0174 upon receipt of that report (Rule 48.2(g)) Oslo (NO). (74) Agent: DEHNS; St. Bride's House, 10 Salisbury Square, London, Greater London EC4Y 8 D (GB). < © (54) Title: COSMETIC FORMULATIONS (57) Abstract: The present invention relates to a topical skin care formulation comprising a) β-(1,3/1,6)- glucan and b) a pro tein-containing plant extract, wherein said plant is of the family Fagaceae; or c) a protein-containing plant extract, wherein said plant is of the genus Vigna. The present invention also relates to a topical skin care formulation comprising -(l,3/l,6)-glucan and an ox- idoreductase. The present invention also relates to an oral composition comprising (i) borage seed oil and astaxanthin; or (ii) vitamin C, collagen hydrolysate, chondroitin sulphate and glucosamine, and also to kits comprising such oral compositions and optionally such topical skin care formulations. The present invention also relates to cosmetic skin treatment method in which these oral com positions and/or topical formulations are used. Cosmetic Formulations The present invention relates to cosmetic compositions used in cosmetics, cosmeceuticals and nutraceuticals, in particular to topical skin care formulations and oral compositions which reduce the visible signs of aging. Aged skin exhibits wrinkles, lacks elasticity, moisture, firmness and density and possesses blemishes and areas of atypical pigmentation. A variety of biological mechanisms are implicated in skin aging, including the degradation of macromolecules such as elastin and collagen. Skin thickness and strength is determined to a large part by the collagen content in the skin's connective tissue. The content of collagen in the skin decreases by about 1% each year in adults and to a greater extent after menopause in women. The cosmetic industry is a large market and there are countless products on offer which are marketed as capable of reducing the visible signs of aging. Cosmetic formulations and compositions include general skin creams, lotions, sera, suncreams and makeup as well as similar products designed for specific use on certain areas of the skin, e.g. the hands, face, neck, decolletage and around the eyes. The effectiveness of anti-aging cosmetics depends in part on the active ingredient or ingredients contained therein. Commonly used ingredients in anti-aging cosmetics include antioxidants, exfoliants, moisturizing agents, proteins and peptides, enzymes and cofactors. Extracts from plants or parts thereof are used in cosmetic compositions since they contain a multitude of active ingredients. Algal, fungal and bacterial extracts are also sometimes used. The effects of the cosmetic compositions can also depend on the concentration of the ingredients and their mode and timings of application. Many skin care companies recommend using a specific treatment program with their products. Despite great demand, many such products and treatments have not been proven to give lasting or major positive effects. For many, skin aging has a psychological impact and causes concern. Despite the current availability of cosmetic formulations and compositions which are marketed as reducing the visible signs of skin aging, there remains a need for new compositions that are effective. The present inventors have identified a novel combination of components for a topical skin care formulation with efficacy in the reduction of the visible signs of skin aging. As well as or as an alternative to reducing the visible signs of skin aging, the formulations may moisturise the skin, lessen the feelings of skin 'tightness' after bathing, provide a protective barrier to UV or other environmental factors, reduce the visibility of pores, reduce the build up of sebum and/or the development of blemishes. In a first aspect, the present invention provides a topical skin care formulation comprising: a) -(1 ,3/1 ,6)-glucan; b) soy protein; and/or c) hydrolysed rice brain protein; and/or d) an oxidoreductase. The term "topical" means that the skin care formulation is suitable and intended for application to the skin of a human subject. Optionally, the topical skin care formulation comprises: a) -(1 ,3/1 ,6)-glucan; b) soy protein; and c) hydrolysed rice brain protein. Preferably the topical skin care formulation comprises: -(1 ,3/1 ,6)-glucan; and an oxidoreductase, and optionally also soy protein and/or hydrolysed rice brain protein. More preferably, the topical skin care formulation comprises a) -(1 ,3/1 ,6)-glucan; b) soy protein; c) hydrolysed rice brain protein; and d) an oxidoreductase. Glucans are a heterogeneous group of glucose polymers found in the cell walls of plants, bacteria and fungi. The basic structural unit in beta-glucans as described herein is a backbone chain and side chains comprising or consisting of β ( 1 →3)- linked glucosyl units. Depending upon the source and method of isolation, beta- glucans have various degrees of branching and of linkages in the side chains. The frequency and type of linkage in the side chains determine the molecule's biological activity. Beta-glucans of fungal and yeast origin are normally insoluble in water, but can be made soluble either by acid hydrolysis or by derivatisation introducing foreign groups like -phosphate, -sulphate, -amine, -carboxymethyl and so forth to the molecule. In Europe, Asia and USA, beta-glucans especially from Bakers' yeast have long been employed as feed additives for animals and as dietary supplements for humans. The glucans used in the formulations of the present invention are β-(1 ,3)-glucans, i.e. glucans containing β-(1 ,3)-linkages. The glucan may be derived from any known source including but not limited to yeast, fungi, algae, grasses, moss, bacteria, seaweed and poaceae (gramineae) such as but not limited to oat, wheat, corn, millet and barley. The glucans of the present invention may consist essentially only of β-(1 ,3)-linked glucose residues. Such glucans include curdlan, which is derived from Agrobacterium biobar, a non pathogenic bacteria and zymosan, which is derived from yeast. Preferably however the glucans are mixed-linkage glucans, i.e. comprising β-(1 ,3)- linked glucose residues in addition to glucose residues linked via other β-linkages, such as β-(1 ,6)-linkages, β-(1 ,4)-linkages and β-(1 ,2)-linkages. Glucans derived from poaceae (gramineae) are typically in the form of a soluble fiber. The bonds between the D-glucose or D-glucopyranosyl units in these glucans are either β- 1 ,3 linkages or β- 1 ,4 linkages. This type of beta-glucan is also referred to as a mixed-linkage β-(1/3, 1/4)-glucan. Another β-(1 ,3/1 ,4)-glucan which may be used in the formulations of the present invention is lichenan (moss starch), which is obtained from mosses such as Cetraria islandica. Preferably, the glucans are -(1 ,3/1 ,6)-glucans, i.e. glucans containing substantially no β-(1 ,4)-linkages. These glucans have a beta-(1 ,3)-backbone, i.e. the backbone comprises beta-(1 ,3)-linked glucopyranose units. Such glucans include essentially linear glucans such as but not limited to laminarin, which is derived from brown algae, Chrysolaminarin, which is derived from photosynthetic heterokonts and Pleuran, which is an insoluble polysaccharide derived from Pleurotus ostreatus. Alternatively, the β-(1 ,3)-glucans of the present inventions may have branched structures. The β-(1 ,3)-glucans may have a beta-(1 ,3)-backbone with multiple single glucose residues each attached thereto by a β-(1 ,6)-linkage.